Objective:
The video interview discusses John Tomtishen’s career, changes across the cell therapy field, and his perspectives on product characterization, CMC, scalability, and bringing future cell therapies to more patients.
Approach:
- Interview: The video was produced in partnership with IBTV and features Tomtishen, Global Head of Cell Therapy Field Application Scientists and Strategic Alliances at Catalent.
- Topics: The discussion covers early product characterization and CMC, technologies and manufacturing strategies for scalability, and steps the industry could take to bring future cell therapies to more patients.
Key Findings:
- Tomtishen explains why developers should prioritize product characterization and CMC early in development.
- The interview explores technologies and manufacturing strategies that could improve scalability.
- Tomtishen shares his perspective on what the industry must do to bring the next generation of transformative cell therapies to more patients.
Interpretation:
The interview presents Tomtishen’s perspective on development and manufacturing considerations in the cell therapy field.
Limitations:
- The provided context does not include the full interview or further details about the technologies and strategies discussed.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
